FAQ on Lantern Pharma's AI Tool for Predicting Blood-Brain Barrier Permeability

What is predictBBB.ai(TM)?

predictBBB.ai(TM) is a public AI module developed by Lantern Pharma that predicts the blood-brain barrier (BBB) permeability of small molecules with high accuracy, sensitivity, and specificity.

Why is predictBBB.ai(TM) significant?

It addresses the pharmaceutical industry’s challenge where only 2–6% of small molecules can cross the BBB, offering a tool with 94% accuracy to potentially accelerate drug development for neurological conditions.

How does predictBBB.ai(TM) work?

The platform leverages billions of molecular data points from Lantern’s proprietary data lake, using synthetic data augmentation and advanced molecular representation to process compounds in real time.

Who developed predictBBB.ai(TM)?

predictBBB.ai(TM) was developed by Lantern Pharma, an AI-driven oncology drug development company.

What is the accuracy of predictBBB.ai(TM)?

The tool boasts 94% accuracy, 95% sensitivity, and 89% specificity in predicting BBB permeability.

What market potential does predictBBB.ai(TM) have?

The BBB technologies market is projected to grow from $1.4 billion in 2023 to $9.85 billion by 2032, indicating strong clinical demand for such technologies.

Where can I find more information about Lantern Pharma?

More information about Lantern Pharma and its developments can be found in the company’s newsroom at https://ibn.fm/LTRN.

What are the implications of predictBBB.ai(TM) for drug development?

By accurately predicting BBB permeability, the tool can significantly reduce the time and cost associated with developing drugs that target the central nervous system, potentially leading to faster availability of treatments for neurological diseases.